QUÉBEC CITY, June 14 /CNW Telbec/ - Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ), (the "Company") a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which will be held June 19 through 22, 2010 at the San Diego Convention Center in San Diego, California. AEZS-130 (Solorel(TM)) is currently in a Phase 3 trial as a diagnostic test for growth hormone deficiency in adults.
Abstract No.851112: "Pharmacological and Toxicological Evaluation of
AEZS-130, a Novel, Oral Synthetic Growth Hormone
Secretagogue//Ghrelin Receptor Agonist for the
Diagnosis of Growth Hormone Deficiency", Babette
Aicher, Peter Schmidt, Elena Bresciani, Vittorio
Locatelli, Daniel Perrissoud, Michael Teifel
Presenter: Dr. Babette Aicher, Associate Director - Screening
& Profiling, Preclinical Development, Aeterna
Date and Time: Sunday, June 20, 2010, 1:30 pm - 3:30 pm
Poster Board No.: P2-340
Location: Halls D-G, San Diego Convention Center
A copy of this abstract is currently available on the ENDO website at www.endo-society.org.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.
For further information: For further information: Investor Relations: Ginette Vallières, Investor Relations Coordinator, (418) 652-8525 ext. 265, email@example.com; Media Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext. 406, firstname.lastname@example.org